Rakuten Securities Inc. Makes New Investment in Pfizer Inc. (NYSE:PFE)

Rakuten Securities Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 47,586 shares of the biopharmaceutical company’s stock, valued at approximately $1,370,000. Pfizer comprises about 1.1% of Rakuten Securities Inc.’s portfolio, making the stock its 18th largest position.

Several other large investors have also made changes to their positions in the business. Guidance Capital Inc. boosted its holdings in Pfizer by 25.0% during the fourth quarter. Guidance Capital Inc. now owns 18,845 shares of the biopharmaceutical company’s stock worth $560,000 after buying an additional 3,765 shares in the last quarter. Lakeside Advisors INC. boosted its holdings in Pfizer by 46.1% during the fourth quarter. Lakeside Advisors INC. now owns 9,512 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 3,000 shares in the last quarter. Sloy Dahl & Holst LLC boosted its holdings in Pfizer by 7.6% during the fourth quarter. Sloy Dahl & Holst LLC now owns 7,417 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 521 shares in the last quarter. Tyche Wealth Partners LLC purchased a new stake in Pfizer during the fourth quarter worth $618,000. Finally, HealthInvest Partners AB purchased a new stake in Pfizer during the fourth quarter worth $1,233,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.8 %

PFE traded down $0.22 during trading hours on Wednesday, reaching $25.69. The company’s stock had a trading volume of 28,885,313 shares, compared to its average volume of 33,467,946. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business’s 50-day moving average is $27.23 and its 200-day moving average is $28.79. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $41.33. The stock has a market cap of $145.47 billion, a PE ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. The firm’s revenue was down 41.3% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.